FY2026 EPS Estimates for Kura Oncology Boosted by Analyst

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Research analysts at Brookline Capital Management upped their FY2026 earnings estimates for shares of Kura Oncology in a research report issued on Thursday, May 1st. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of $0.88 per share for the year, up from their prior estimate of $0.84. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology's FY2027 earnings at $3.09 EPS, FY2028 earnings at $5.92 EPS and FY2029 earnings at $12.20 EPS.

Other analysts also recently issued research reports about the stock. Barclays reduced their price objective on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. StockNews.com cut shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. BTIG Research downgraded shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Monday, April 28th. Finally, Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.89.

Kura Oncology Trading Down 1.7 %

Shares of Kura Oncology stock traded down $0.10 on Monday, hitting $5.90. 161,831 shares of the company's stock traded hands, compared to its average volume of 1,165,181. The company has a fifty day moving average of $6.60 and a two-hundred day moving average of $9.31. Kura Oncology has a one year low of $5.41 and a one year high of $23.48. The company has a market capitalization of $510.79 million, a price-to-earnings ratio of -2.50 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently bought and sold shares of the company. Virtus ETF Advisers LLC lifted its position in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after purchasing an additional 3,061 shares in the last quarter. Harbor Advisors LLC purchased a new stake in Kura Oncology in the 4th quarter valued at about $87,000. Pallas Capital Advisors LLC bought a new position in shares of Kura Oncology during the 1st quarter worth approximately $66,000. E Fund Management Co. Ltd. purchased a new position in shares of Kura Oncology in the 4th quarter worth approximately $90,000. Finally, Corton Capital Inc. bought a new position in shares of Kura Oncology in the fourth quarter valued at approximately $99,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.